Research Interests:Translational Bioinformatics Biomarker Discovery Companion Diagnostics Cancer Therapeutics Precision Medicine Immuno-Oncology
About Song Liu
I graduated from the University of Science and Technology of China in 2002. I obtained my PhD from The State University of New York at Buffalo in 2006, and received the post-doctoral training at Howard Hughes Medical Institute (HHMI) at Columbia University.
I was appointed to an Assistant Professor position at Roswell Park Comprehensive Cancer Center in 2009, an Associate Professor position in 2012, and a Full Professor position in 2016.
I completed the General Management Program at the Wharton School of Business, University of Pennsylvania in 2018 (WMP’18). I graduated with an MBA from the Massachusetts Institute of Technology Sloan School of Management in 2023.
- Professor of Oncology
- Vice Chair, Clinical Research
- Director of Biostatistics & Bioinformatics, CCSG Shared Resources
- Department of Biostatistics & Bioinformatics
Education and Training:
- BS - 2002 - University of Science and Technology of China
- PhD - 2006 - State University of New York at Buffalo
- MBA - 2023 - MIT Sloan School of Management
- Executive Education: General Management Program - Wharton School of Business, University of Pennsylvania
- Post-doctoral Fellow - Howard Hughes Medical Institute (HHMI) at Columbia University
- American Association for Cancer Research (AACR)
- Society for Immunotherapy of Cancer (SITC)
Dr. Liu is a Professor of Oncology and Vice Chair of the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. His research revolves around the development and application of computational methods to address biologically important and clinically significant questions in cancer diagnosis and treatment.
Dr. Liu is one of the Principal Investigators of the Data Management and Resource-Sharing Center for the Immuno-Oncology Translational Network (IOTN), an NCI-funded Cancer Moonshot flagship initiative devoted to cancer immunotherapy. He is one of the Principal Investigators of the Coordinating and Data Management Center for the Acquired Resistance to Therapy Network (ARTNet), an NCI-funded Cancer Moonshot initiative addressing therapy resistance. He is also one of the Principal Investigators of the Data and Resource Coordination Center for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT), an NCI-funded research initiative focusing on precision cancer prevention and interception.
Dr. Liu is the founding director of the Roswell Park CCSG Bioinformatics Core. He leads the Roswell Park CCSG Biostatistics & Bioinformatics Shared Resource. He co-leads the Biostatistics and Bioinformatics Core of NCI-funded Roswell Park – University of Chicago Ovarian Cancer SPORE, and co-leads its Individual Project #2, which seeks to develop dendritic cell vaccines loaded with patient-specific neoantigen peptides.
Dr. Liu is an Associate Editors-in-Chief of Genomics, Proteomics & Bioinformatics (GPB), and he chairs the Big Data and Data Sharing Committee at the Society of Immunotherapy of Cancer (SITC). He is the author of more than 250 peer-reviewed publications, which have been cited over 15,000 times.
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, Liu S, Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ, Fenstermaker RA. Journal of Clinical Oncology, 2023;41(7):1453-1465.
Prostate cancer progression relies on the mitotic kinase citron kinase. Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, Venkadakrishnan VB, Macdonald JD, Dahiya UR, Ghanem Y, Bachour S, Su Y, DePriest AD, Lee S, Muldong M, Kim HT, Kumari S, Valenzuela MM, Zhang D, Hu Q, Cortes Gomez E, Dehm SM, Zoubeidi A, Jamieson CAM, Nicolas M, McKenney J, Willard B, Klein EA, Magi-Galluzzi C, Stauffer SR, Liu S*, Heemers HV*. Cancer Research 2023. doi: 10.1158/0008-5472.CAN-23-0883. PMID: 37801613
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies. Annapragada A, Sikora AG, Marathe H, Liu S, Demetriou M, Fong L, Gao J, Kufe D, Morris ZS, Vilar E, Sharon E, Hutson A, Odunsi K. Journal of the National Cancer Institute 2023;115(11):1262-1270.
Understanding Drug Sensitivity and Tackling Resistance in Cancer. Tyner JW*, Haderk F*, Kumaraswamy A*, Baughn LB*, Van Ness BG*, Liu S*, Marathe H*, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD; for the Drug Resistance and Sensitivity Network. Cancer Research 2022;82(8):1448-1460.
Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Herr MM, Hahn T, Samur M, Munshi N, Liu S*, McCarthy PL*, Hillengass J*. Nature Communications 2022;13(1):807.
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Science Translational Medicine 2022;14(636):eabg8402.
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity with Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan YP, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, Lipkin SM, Kloor M. Gastroenterology 2021;161(4):1288-1302.e13.
CD8+ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Li K, Li T, Feng Z, Huang M, Wei L, Yan Z, Long M, Hu Q, Wang J, Liu S, Sgroi DC, Demehri S. Science Advances 2021;7(25):eabd8936.
MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK*, Liu S*, Kufe D*. Journal for ImmunoTherapy of Cancer 2021;9(1):e002115.
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Pan Y, Kadash-Edmondson K, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte O, Xing Y. Trends in Pharmacological Sciences 2021; 42(4), 268-282.
Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. JAMA Oncology 2021;7(1):78-85.
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Proceedings of the National Academy of Sciences 2021;118(8):e2025840118.
Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden. Wei L, Christensen SR, Fitzgerald ME, Graham J, Hutson ND, Zhang C, Huang Z, Hu Q, Zhan F, Xie J, Zhang J, Liu S, Remenyik E, Gellen E, Colegio OR, Bax M, Xu J, Lin H, Huss WJ, Foster BA, Paragh G. Science Advances 2021 Jan 1;7(1):eabd7703.
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng A, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Tumor Neoantigen Selection Alliance; Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Cell 2020;183(3):818-834.e13.
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI*, Liu S*, Ito F. Nature Communications 2020;11(1):5415.
Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S*, Tang DG*. Nature Communications 2020;11(1):2089